Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
NCT07213076
·
clinicaltrials.gov ↗
COMPLETED
Status
350
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Sponsor
AstraZeneca
Collaborators
[object Object]